Celebrex Long-Term Safety Study Planned
Pfizer will work with FDA to design a long-term safety study for Celebrex following the agency's decision to recommend a "black box" warning on the COX-2 inhibitor's increased risk for cardiovascular events
Pfizer will work with FDA to design a long-term safety study for Celebrex following the agency's decision to recommend a "black box" warning on the COX-2 inhibitor's increased risk for cardiovascular events